Start here if you're new
what it is
Cassava Sciences develops Alzheimer’s drug programs and a blood test using a 30-person team.
how it gets paid
Last year Cassava Sciences made n/a in revenue.
what just happened
The latest quarter showed a -$1.62 EPS loss.
At a glance
C++ balance sheet — some cracks in the foundation
40/100 earnings predictability — expect surprises
-$3.78 fy2024 eps est
1.2 beta
~$96M market cap
xvary composite: 41/100 — below average
What they do
Cassava Sciences develops Alzheimer’s drug programs and a blood test using a 30-person team.
Cassava has exclusive worldwide rights to 2 investigational programs. That means no third-party royalties, so the math stays simple. You get a tiny team, 30 employees, and $0M in TTM revenue. That is not a fortress. It is a waiting room.
How they make money
n/a
annual revenue
The products that matter
pre-revenue drug development
Lead clinical program
~$96M market cap · one disclosed lead asset
this is effectively the whole company. with no revenue and one disclosed lead program, the stock is pricing scientific probability rather than business execution.
binary setup
Key numbers
-$3.78
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for SAVA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter showed a -$1.62 EPS loss.
The company is still pre-revenue, with $0M in TTM revenue and no gross margin figure in the provided filing data. That leaves you staring at losses, not a finished business.
$0M
revenue
-$1.62
eps
n/a
n/a
loss per share
The number that mattered was -$1.62 EPS. You are still funding research, not a company with sales.
source: company earnings report, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The central risk is clinical failure in the only disclosed lead program. For Filana, bad data is not a setback to one business line. It is the whole equity story breaking at once.
med
Lead program fails
There is one disclosed clinical asset carrying the narrative. If a pivotal readout disappoints, the market does not have another product, revenue stream, or late-stage pipeline asset to fall back on.
Impact: the current ~$96M market value is tied to a scientific premise that still needs proof.
med
Cash burn forces dilution
No revenue plus a FY2024 EPS estimate of -$3.78 means outside capital still matters. If fresh money arrives before value-creating data, your ownership gets smaller before the thesis gets stronger.
Impact: dilution can cap upside even if the science eventually works.
med
Timeline slips keep resetting the clock
Clinical-stage biotechs live on calendars. Delays extend the pre-revenue period, increase financing pressure, and give the market more time to doubt a single-asset file.
Impact: with no commercial business underneath, time itself becomes a cost center.
med
Thin coverage magnifies moves
This page only has one analyst target at $8.00 and institutional ownership detail is still being compiled. Thin coverage does not tell you the stock is wrong. It tells you price discovery can get messy fast.
Impact: with a $2.80 share price and thin external anchors, headline reactions can outrun fundamentals in both directions.
With n/a revenue, one disclosed lead asset, and 5/100 price stability, negative trial news and financing pressure would hit the same ~$96M equity story at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
Losses still matter more than sales growth
FY2024 EPS is estimated at -$3.78 and revenue is still n/a. Until that changes, each quarter is mostly a cash-consumption update.
calendar
Ticker change to FLNA on March 11, 2026
The rebrand is real. The thesis improves only if the underlying data improve too.
trend
Price stability sits at 5 / 100
That is a reminder that this stock reacts to headlines and funding expectations faster than to any steady operating trend.
coverage risk
Thin analyst coverage leaves you with fewer external anchors
One analyst price target of $8.00 is a data point, not broad market conviction. The catch: thin coverage can amplify moves in both directions.
Analyst rankings
earnings predictability
40 / 100
in human-speak, analysts do not have a stable operating model to lean on here, so surprises come with the territory.
beta
1.2
Market sensitivity is only slightly above average. The harder part is the company-specific headline risk layered on top.
source: institutional data
Institutional activity
institutional ownership data for SAVA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive